TDC
KITE

Thompson Davis & Co’s Kite Pharma, Inc. KITE Stock Holding History

Thompson Davis & Co’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-125
Closed -$13K – 1261
2017
Q2 		$13K Hold
125
– – 0.02% 598
2017
Q1 		$10K Buy
125
+50
+67% +$3.09K 0.01% 704
2016
Q4 		$3K Buy
+75
New +$3.68K 0.01% 1000

Other funds holding KITE

CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCSAM
Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Thompson Davis & Co's KITE Position: Q3 2017 in Review

Thompson Davis & Co sold out of Kite Pharma, Inc. (KITE) in Q3 2017, closing a stake of 125 shares — an estimated $13K sold.

Thompson Davis & Co first reported a position in KITE in Q4 2016 and held it in 3 quarters. The position peaked at $13K in Q2 2017. 244 funds tracked by Wall St. Rank hold KITE as of Q3 2017.

  • Thompson Davis & Co reported no remaining Kite Pharma, Inc. position as of Q3 2017 after selling out during the quarter.
  • Thompson Davis & Co sold 125 Kite Pharma, Inc. shares in Q3 2017, an estimated $13K.
  • Thompson Davis & Co first reported a position in Kite Pharma, Inc. in Q4 2016 and held it in 3 quarters.
  • Thompson Davis & Co's Kite Pharma, Inc. position peaked at $13K in Q2 2017.
  • 244 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2017.

Based on Thompson Davis & Co's 13F filing for Q3 2017, filed 30 Oct 2017.